A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program

Sexual Health

Volumn 4, Issue 3, 2007, Pages 165-175

  Kulasingam, Shalini ^a   Connelly, Luke ^b   Conway, Elizabeth ^c   Hocking, Jane S ^d   Myers, Evan ^e   Regan, David G ^f   Roder, David ^g   Ross, Jayne ^h   Wain, Gerard ⁱ  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CSL LIMITED   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g CANCER COUNCIL SOUTH AUSTRALIA   (Australia)

^h Jayne Ross and Associates   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION;

ADOLESCENT; AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MARKOV CHAINS; MASS IMMUNIZATION; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS;

EID: 34548301812     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH07043     Document Type: Article

References (61)

1. Department of Health and Aging Australian Government. The National Cervical Screening Program. Facts and key statistics. 2007. Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/ facts [accessed 8 June, 2007]
2. Australian Institute of Health and Welfare (AIHW). Cervical screening in Australia 2002-3. Cancer Series No. 31, Canberra: AIHW; 2005.
3. Report of the Evaluation Steering Committee. The interim evaluation of the organised approach to preventing cancer of the cervix 1991-95. Report No. 27. Canberra: Australian Government Publishing Service; 1995.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995; 87: 796-802. doi: 10.1093/jnci/87.11.796
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. doi: 10.1056/NEJMoa021641
6. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73. doi: 10.1038/sj.bjc.6600688
7. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51. doi: 10.1056/NEJMoa020586
8. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8. doi: 10.1016/S1470-2045(05)70101-7
9. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65. doi: 10.1016/S0140-6736(04) 17398-4
10. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55. doi: 10.1016/S0140-6736(06)68439-0
11. Department of Health and Aging Australian Government. Australian Government funding of Gardasil. 2006. Available from: http://www.health.gov.au/ internet/wcms/publishing.nsf/Content/4754B33584405E06CA2572220008CFA8/ $File/Gardasilfunding-factsheet.pdf [accessed 8 June, 2007]
12. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in lowgrade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-64. doi: 10.1158/1055-9965.EPI-04-0812
13. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5. doi: 10.1038/sj.bjc.6601024
14. McCrory DC, Matchar DB, Bastian L, Datta S, Hasselblad V, Hickey J, et al. Evaluation of cervical cytology. Evidence Report/Technology Assessment No. 5 (Prepared by Duke University under Contract No. 290-97-0014). AHCPR Publication No. 99-E010. Rockville, MD: Agency for Health Care Policy and Research; 1999.
15. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-71.
16. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 14-9.
17. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003; 168: 421-5.
18. Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87. doi: 10.1086/425907
19. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the agerelated patterns for high-risk and low-risk types. Int J Cancer 2000; 87: 221-7. doi: 10.1002/1097-0215(20000715)87:2〈221::AIDIJC11〉3.0.CO;2-2
20. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-53.
21. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336-43.
22. Hoyer H, Scheungraber C, Kuehne-Heid R, Teller K, Greinke C, Leistritz S, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer 2005; 116: 136-43. doi: 10.1002/ijc.20955
23. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191: 731-8. doi: 10.1086/427557
24. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002; 186: 462-9. doi: 10.1086/341782
25. Yokoyama M, Iwasaka T, Nagata C, Nozawa S, Sekiya S, Hirai Y, et al. Prognostic factors associated with the clinical outcome of cervical intraepithelial neoplasia: a cohort study in Japan. Cancer Lett 2003; 192: 171-9. doi: 10.1016/S0304-3835(02)00715-2
26. Sastre-Garau X, Cartier I, Jourdan-Da Silva N, De Cremoux P, Lepage V, Charron D. Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype. Obstet Gynecol 2004; 104: 751-5.
27. Kataja V, Syrjanen K, Mantyjarvi R, Vayrynen M, Syrjanen S, Saarikoski S, et al. Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data. Eur J Epidemiol 1989; 5: 1-7. doi: 10.1007/BF00145037
28. Matsumoto K, Yasugi T, Oki A, Fujii T, Nagata C, Sekiya S, et al. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. Cancer Lett 2006; 231: 309-13. doi: 10.1016/j.canlet.2005.02.023
29. De Aloysio D, Milif. L, Iannicelli T, Penacchioni P, Bottiglioni F. Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection. Acta Obstet Gynecol Scand 1994; 73: 420-4.
30. Brestovac B, Harnett GB, Smith DW, Shellam GR, Frost FA. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 2005; 76: 106-10. doi: 10.1002/jmv.20330
31. Chen S, O'Sullivan H, Tabrizi SN, Fairley CK, Quinn MA, Garland SM. Prevalence and genotyping of HPV in cervical cancer among Australian women. Int J Gynaecol Obstet 1999; 67: 163-8. doi: 10.1016/S0020-7292(99)00167-8
32. Liu JH, Huang X, Liao GW, Li JD, Li YF, Li MD, et al. [Human papillomavirus infection and other risk factors for cervical cancer in Chinese and Australian patients] Zhonghua Yi Xue Za Zhi 2003; 83: 748-52.
33. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006; 16: 1017-24. doi: 10.1111/j.1525-1438.2006.00453.x
34. Australian Institute of Health and Welfare (AIHW). General Record of Incidence of Mortality (GRIM) Books. 2005. Available from: http://www.aihw.gov. au/mortality/data/grim_books_national.cfm [accessed 8 June, 2007]
35. Australian Institute of Health and Welfare (AIHW). Separation, patient day and average length of stay statistics by Australian Refined Diagnosis Related Group (AR-DRG) Version 5.0/5.1. Australia, 1998-99 to 2004-05. Canberra: AIHW; 2005.
36. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 1999. Incidence and mortality 1999. Adelaide: Openbook Publishers; 2000.
37. Davy MLJ, Dodd TJ, Luke CJ, Roder DM. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003; 101: 38-45. doi: 10.1016/S0029-7844(02)02275-5
38. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101. doi: 10.1002/ijc.21955
39. Morrell S, Mamoon H, O'Callaghan J, Taylor R, Ross J, Wain G. Early cervical cancer rescreening. J Med Screen 2002; 9: 26-32. doi: 10.1136/jms.9.1.26
40. Medical Services Advisory Committee. Human papillomavirus testing in women with cytological prediction of low-grade abnormality: assessment report 12b. Canberra: MSAC; 2002.
41. National Health and Medical Research Council. National Cervical Screening Program. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: NHMRC; 2005.
42. Gynaecological Oncology Study Group. Gynaecological oncology clinical practice guidelines. Sydney: GMTT; 2004.
43. Blomfield P, Davy M, Hammond I, Wain G. The new NH&MRC guidelines for management of abnormal Pap smears in asymptomatic Australian women. Obstet Gynecol 2005; 7: 25-7.
44. Skinner R, Nolan T. Adolescent hepatitis B immunisation - should it be the law? Aust NZ J Public Health 2001; 25: 230-3.
45. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83. doi: 10.1016/j.vaccine.2006.04.068
46. Regan DG, Philip DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007; 4: 147-63. doi: 10.1071/SH07042
47. Medicare Australia. Australian Government. Medicare benefits schedule. 2006. Available from: http://www.medicareaustralia.gov.au/providers/ health_statistics/statistical_reporting/medicare.htm [accessed 8 June, 2007]
48. Department of Health and Aging Australian Government. Medicare statistics - March quarter 2006. Group B Tables - selected statistics by broad type of service. 2006. Available from: http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/medstat-mar06-analysis-b [accessed 8 June, 2007]
49. Municipal Association of Victoria. Cost of Victorian local government immunisation services; Melbourne: MAV; 2004.
50. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection. Visual analog scales versus time tradeoff elicitation. Proceedings of the 21st International Papillomavirus Conference, 2004 February 20-27; Mexico City, Mexico.
51. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Version 41. Canberra: PBAC; 2006.
52. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15.
53. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-9. doi: 10.1001/jama.290.6.781
54. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138. doi: 10.1371/journal.pmed. 0030138
55. Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, et al. Enrolment of 22 000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006; 17: 517-21. doi: 10.1258/095646206778145550
56. Pharmaceutical Benefits Scheme. Department of Health and Aging. Australian Government. Government funds Gardasil. 2006. Available from: http://www.pbs.gov.au/html/healthpro/news/article?id=NEWS-2006-11-29- Aust_Govt_Funds_Gardasil.xml [accessed 8 June 2007]
57. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence; 2004.
58. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
59. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88-100. doi: 10.1093/epirev/mxj006
60. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
61. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23.